The sales are very small relative to market cap and follow a positive earnings report, making them likely routine portfolio adjustments. Monitor for any larger insider selling or changes in forward guidance that could signal a shift in management's outlook.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $370.48entry
- T+1 · 4d ago −1.11%α −0.75% · $366.36
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two senior executives at Bio-Rad (President & COO and EVP/President of Life Science Group) sold a combined $899K in open-market shares on November 9, 2026, eight days after the company reported a Q3 earnings beat with revenue slightly above consensus but maintained guidance for a potential full-year revenue decline. The sales are not under 10b5-1 plans and follow the earnings release, suggesting possible profit-taking or portfolio rebalancing after the positive results.
Key Financial Metrics
Key Facts
- President & COO Jonathan DiVincenzo sold 919 shares at $390.47 for $359K on Nov 9, 2026
- EVP/President LSG James Barry sold 1,400 shares at $385.63 for $540K on Nov 9, 2026
- Total open-market sales of $899K represent ~0.009% of Bio-Rad's $10.4B market cap
- Neither sale was executed under a 10b5-1 plan
- Sales occurred 8 days after Q3 2026 earnings beat (non-GAAP EPS $2.65 vs $2.23 consensus)
Financial Impact
Total insider sales of $899K, negligible relative to $10.4B market cap
Risk Factors
- Sales by two senior executives on the same day could indicate coordinated profit-taking
- No 10b5-1 plan provides a pre-planned defense for the timing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BIO-1794499138165 |
Track record
9 reports on BIO
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Viewing Entry $370.48 Now $360.26 −2.76% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $386.00 Now $360.26 −6.67% settles Nov 18
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
- Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $388.31 to $360.26 Now $360.26 +7.22% ▲ +7.22% +5.53% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $369.00 to $370.48 Now $360.26 −2.37% ▲ +0.40% −2.89% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $385.12 to $379.99 Now $360.26 −6.46% ▼ −1.33% −0.62% vs SPY
- Sep 10, 20269w ago Court Ruling Bearish 5/10 Entry $369.32 to $376.41 Now $360.26 +2.45% ▼ −1.92% −2.26% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $285.94 to $282.44 Now $360.26 +25.99% ▼ −1.22% −1.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers